Clinical Edge Journal Scan

Risk for herpes zoster in RA higher with tsDMARDs/bDMARDs vs csDMARDs


 

Key clinical point: In patients with rheumatoid arthritis (RA), treatment with targeted synthetic and biologic disease-modifying antirheumatic drugs (tsDMARDs/bDMARDs) vs conventional synthetic DMARDs (csDMARDs) was associated with a significantly higher risk for herpes zoster (HZ).

Major finding: Compared with csDMARDs, Janus kinase inhibitors (adjusted hazard ratio [aHR], 3.66; P less than .0001), monoclonal anti-tumor necrosis factor antibodies (aHR, 1.63; P = .0042), and B-cell targeted treatment (aHR, 1.57; P = .0355) were associated with a significantly higher risk for HZ.

Study details: The data come from an analysis of 13,991 patients with RA from the German RABBIT register, which included patients who initiated tsDMARD/bDMARD or csDMARD treatment after at least 1 prior DMARD.

Disclosures: RABBIT is supported by a joint, unconditional grant from AbbVie, Amgen, BMS, Celltrion, Fresenius Kabi, Hexal, Lilly, MSD, Viatris, Pfizer, Roche, Samsung Bioepis, Sanofi-Aventis, and UCB. A Strangfeld, A Zink, GR Burmester, and J Braun declared receiving speaker fees, honoraria, consulting, and/or grants from various sources.

Source: Redeker I et al. Ann Rheum Dis. 2021 Jul 28. doi: 10.1136/annrheumdis-2021-220651 .

Recommended Reading

Can a blood-based test predict TNFi nonresponse in RA?
MDedge Rheumatology
Tocilizumab shortage continues as pandemic wears on
MDedge Rheumatology
New options explored for sarcopenia in rheumatic diseases
MDedge Rheumatology
Parental smoking linked to more adult RA in women
MDedge Rheumatology
In RA patients, multiple comorbidities lower odds of disease control
MDedge Rheumatology
NIH to study COVID vaccine booster in people with autoimmune disease
MDedge Rheumatology
Rheumatoid arthritis: Olokizumab shows promise in phase 3
MDedge Rheumatology
Increased risk for vertebral fractures persists even with low-dose oral glucocorticoids for RA
MDedge Rheumatology
Real-world comparative assessment of tofacitinib and baricitinib in RA
MDedge Rheumatology
Higher anti-PC autoantibodies indicate lower risk for cardiovascular events in early RA
MDedge Rheumatology